NCT05383339 Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
| NCT ID | NCT05383339 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Autoimmune Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,250 participants |
| Start Date | 2022-11-29 |
| Primary Completion | 2031-11-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,250 participants in total. It began in 2022-11-29 with a primary completion date of 2031-11-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this work is to identify, in patients with autoimmune diseases, systemic vasculitis and autoinflammatory disease, cytokine and lymphocyte biomarkers of activity of these diseases to identify follow-up biomarkers, in order to personalize the follow-up and the treatments for each patient. Immunological data will be obtained from biological samples collected as part of the usual patient care pathway (Blood and tissues sampling) The study will take place in the Department of Internal Medicine and Clinical Immunology (DMIIC), that is certified as the National Reference Centre for Rare Systemic Autoimmune Diseases and the National Reference Centre for Inflammatory Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA). Its objective is to contribute to the advancement of fundamental knowledge in immunology, in particular to develop prognostic biomarkers of the activity of autoimmune diseases, systemic vasculitis and autoinflammatory diseases by using blood tests.
Eligibility Criteria
Inclusion Criteria: * Patients of 18 years of age or older * Patients with autoimmune systemic disease, systemic vasculitis or autoinflammatory disease, defined by the international criteria in force for each pathology, among the following: * Connectivities: lupus, Sjögren syndrome, antiphospholipid syndrome, mixed connectivity and Sharp syndrome, scleroderma, myositis * Vasculitis of large, small and medium vessels: giant cell arteritis, Takayasu arteritis, Behçet disease, ANCA vasculitis, cryoglobulinemic vasculitis, IgA vasculitis (rheumatoid purpura) * Buerger's disease (obliterating thromboangitis) * Granulomatosis and sarcoidosis * Uveitis * Monogenic and polygenic autoinflammatory diseases: family Mediterranean fever, TRAPS, CAPS, chronic atrophic polychondritis, pericarditis * Recurrent fevers and unexplained inflammatory syndromes * Inflammatory amyloidosis * Patients affiliated to French social security Exclusion Criteria: * Vulnerable populations: * Persons deprived of liberty by judicial or administrative decision; * Persons receiving psychiatric care without their consent; * Adult subject to a legal protection measure (guardianship, curatorship); * Persons unable to give their consent.
Contact & Investigator
David Saadoun, Professor
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05383339 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05383339 currently recruiting?
Yes, NCT05383339 is actively recruiting participants. Contact the research team at david.saadoun@aphp.fr for enrollment information.
Where is the NCT05383339 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05383339 clinical trial?
NCT05383339 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is David Saadoun, Professor at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 2,250 participants.